Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against TechTarget, Inc. and Aldeyra Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices [1] TechTarget, Inc. (NASDAQ:TTGT) - On December 6, 2024, TechTarget announced that its previous financial statements were being restated due to identified errors, leading to a share price decline from $25.54 to $23.48, a drop of $2.09 per share [2] - On March 31, 2025, TechTarget disclosed it would be unable to timely file its 2024 Annual Report, indicating a potential pre-tax non-cash goodwill impairment charge of approximately $70 million to $110 million for the fiscal year, resulting in a share price drop from $14.81 to $12.76, a decline of $2.05 per share [3] Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - On April 3, 2025, Aldeyra received a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, stating that the application failed to demonstrate efficacy in adequate studies, which led to a sharp decline in stock price during intraday trading [4]